In The News
Targeted Oncology

Sotatercept Boosts Hemoglobin in MPN-Associated Myelofibrosis

Cancer Network

Immunotherapies Could Play Role in CALR-Positive Myeloproliferative Neoplasms (Video)


Expert Highlights RESPONSE Results With Ruxolitinib in Polycythemia vera

Targeted Oncology

Ropeginterferon Alfa-2b Has Long-Term Benefits in Polycythemia Vera

MPNforum Magazine

Fedratinib Rises

Hematol News

FDA Approves Test for Hematologic Cancer Detection


Risk of Age-Related Macular Degeneration Higher With Myeloproliferative Neoplasms


European LeukemiaNet Study on the Reproducibility of Bone Marrow Features in Masked Polycythemia Vera


Myeloproliferative Neoplasms and Myelofibrosis: New Treatment Guidelines

Cancer Network

Fedratinib Reduced Spleen Volume in Ruxolitinib-Resistant Myelofibrosis

Oncol Nurse Adv

Unexplained Leukocytosis, Thrombocytosis in MPNs Warrants Evaluation for CML

PR Newswire

AOP Orphan and PharmaEssentia Announce Latest Clinical Results for Ropeginterferon alfa-2b in Polycythemia Vera

HemOnc Today

Lack of Transfusion Capabilities Linked to Underuse of Hospice for Blood Cancers

The Role of LNK/SH2B3 Genetic Alterations in Myeloproliferative Neoplasms and Other Hematological Disorders

Oncology Nursing News

Patients Often Not as Confident in Their Oral Medication Regimens as They Seem


Clinical Trials Are Crucial to Advance MPN Treatment

The ASCO Post

Reduced-Intensity vs Standard Conditioning Followed by ASCT in Myelodysplastic Syndrome

National Cancer Institute

Myelodysplastic/Myeloproliferative Neoplasms Treatment (PDQ®)

Oncology Nurse Advisor

Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis

Modern Pathology

3q26.2/EVI1 Rearrangement is Associated With Poor Prognosis in Classical Philadelphia Chromosome-Negative Myeloproliferative Neoplasms

Medscape Oncology

Pacritinib Well Tolerated and Helpful in Myelofibrosis

ONS Voice

FDA Approves Marketing Ipsogen JAK2 RGQ PCR Kit to Help Evaluate Suspected Polycythemia Vera

Leukemia Foundation MPN News (PDF download)

Genetic Profiling: The Basis of a Groundbreaking Myelofibrosis Study

MPN Advocacy & Education

The Ultimate Blood Brothers


Do We Know What Matters Most to Cancer Patients?

Oncology Nurse Advisor

Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis

Mayo Clinic

Online Survey To Measure Nutritional Needs in Patients With Myeloproliferative Neoplasms


Genetic Profiling Can Guide Stem Cell Transplantation for Patients With Myelodysplastic Syndromes


High Rates of Symptoms, Impairment, With Myeloproliferative Neoplasms


Landscape for Myeloproliferative Disorders Becoming More Defined With Improved Treatments, Biomarkers

Oncology Nurse Advisor

Anxiety, Distress Common Among Patients With BCR-ABL-Negative MPNs

New Mexico Cancer Center News

Duration of Blood Storage Does Not Affect Outcomes for Patients Requiring Blood Transfusions

Northwestern Now

Rewired Cells Show Promise for Targeted Cancer Therapy

Cancer Connect

Interferon No Better Than Hydroxyurea and Associated With Worse Side Effects in Polycythemia Vera and Essential Thrombocythemia

Cancer Connect

5-Year Survival Improved With Early Use of Ruxolitinib in Myelofibrosis

MPN Advocacy & Education

Women with Myeloproliferative Neoplasms Appear to Have Successful Pregnancies

Cancer Connect

About PCROWD, Dana-Farber’s Tissue-Banking Study for Patients with Myeloproliferative Neoplasms, Smoldering Multiple Myeloma, Smoldering Waldenstrom’s Macroglobulemia, and Early Myelodysplastic Syndromes


Personalizing Treatment From Start to Finish in Polycythemia Vera

Cancer Connect

Jakafi Safe and Effective in Polycythemia Vera

Medical Life Sciences

New NCCN Guidelines Outline Diagnosis, Treatment Strategies for Myeloproliferative Neoplasms

Medscape Oncology

Ipilimumab Shows Impressive Activity After HSCT Failure


Study Examines Sexuality Symptoms in Patients With Myeloproliferative Neoplasms

All Symptomatic Polycythemia Vera Patients may Benefit From Treatment With a JAK2 Inhibitor

The MPN Research Foundation

Anti-Fibrotic Drug Recruiting Patients Across the Country for Phase 2 Clinical Trial